文献速递临床免疫临床生化

第二代微流控检测定量血中胶质纤维酸性蛋白:验证及与两种成熟检测的比较

Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays.
PubMed 文献 · Clin Chem Lab Med · 2024-02-07

该研究验证了新型第二代Ella检测定量血清GFAP的分析性能,并在210例神经系统疾病患者队列中与基于微珠的单分子阵列(Simoa)及自制GFAP检测进行比较。结果显示第二代Ella检测具有较高可靠性与重复性,与Simoa强相关(r=0.91),各检测在诊断分组中呈现相同GFAP分布模式。

要点

  • 第二代Ella检测批内变异10%、批间变异12%,检测限0.9 pg/mL,定量下限2.8 pg/mL。
  • 与Simoa相关性r=0.91(95%CI 0.88-0.93,p<0.0001),与自制免疫检测r=0.77(95%CI 0.70-0.82,p<0.0001)。
  • Simoa分析灵敏度更高,但第二代Ella因稳健易用可能适合日常临床GFAP检测。

核心结论

  • 第二代Ella检测定量血清GFAP具有高可靠性、精密度和重复性。
  • Simoa的分析灵敏度更高,但新微流控检测因稳健性和易用性可能适用于日常临床工作流程。

研究设计与样本

  • 验证研究,评估第二代Ella检测定量血清GFAP的分析性能。
  • 在包含210例神经系统疾病患者的临床队列中,与基于微珠的Simoa及自制GFAP检测进行比较。

主要发现

  • 验证实验显示批内变异10%、批间变异12%、检测限0.9 pg/mL、定量下限2.8 pg/mL。
  • 血清样本经历最多五次冻融循环、4 °C及室温120 h后变异小于20%。
  • 三种检测在临床队列不同诊断组中显示相同的GFAP分布模式。
  • 第二代Ella与Simoa强相关:r=0.91(95%CI 0.88-0.93),p<0.0001。
  • 第二代Ella与自制免疫检测相关:r=0.77(95%CI 0.70-0.82),p<0.0001。

关键数值与推荐

  • 批内变异10%,批间变异12%。
  • 检测限0.9 pg/mL,定量下限2.8 pg/mL。
  • 最多五次冻融循环、4 °C和室温120 h后血清样本变异小于20%。
  • 与Simoa相关性r=0.91(95%CI 0.88-0.93),p<0.0001;与自制免疫检测r=0.77(95%CI 0.70-0.82),p<0.0001。

临床怎么用

  • 第二代Ella检测因稳健、易用,可能可用于日常临床工作中的GFAP分析。
  • 临床选用检测方法时需权衡:Simoa分析灵敏度更高,第二代Ella更便于常规开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Increased levels of glial fibrillary acidic protein (GFAP) in blood have been identified as a valuable biomarker for some neurological disorders, such as Alzheimer's disease and multiple sclerosis. However, most blood GFAP quantifications so far were performed using the same bead-based assay, and to date a routine clinical application is lacking. METHODS: In this study, we validated a novel second-generation (2nd gen) Ella assay to quantify serum GFAP. Furthermore, we compared its performance with a bead-based single molecule array (Simoa) and a homemade GFAP assay in a clinical cohort of neurological diseases, including 210 patients. RESULTS: Validation experiments resulted in an intra-assay variation of 10 %, an inter-assay of 12 %, a limit of detection of 0.9 pg/mL, a lower limit of quantification of 2.8 pg/mL, and less than 20 % variation in serum samples exposed to up to five freeze-thaw cycles, 120 h at 4 °C and room temperature. Measurement of the clinical cohort using all assays revealed the same pattern of GFAP distribution in the different diagnostic groups. Moreover, we observed a strong correlation between the 2nd gen Ella and Simoa (r=0.91 (95 % CI: 0.88-0.93), p<0.0001) and the homemade immunoassay (r=0.77 (95 % CI: 0.70-0.82), p<0.0001). CONCLUSIONS: Our results demonstrate a high reliability, precision and reproducibility of the 2nd gen Ella assay. Although a higher assay sensitivity for Simoa was observed, the new microfluidic assay might have the potential to be used for GFAP analysis in daily clinical workups due to its robustness and ease of use.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Fazeli B, Gómez de San José N, Jesse S, et al. Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays. Clin Chem Lab Med. 2024. PMID: 38353147. doi:10.1515/cclm-2023-1256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。